And I just don’t believe in it as much as I do having our customers talk to product heads. And why is that? Because if you’re an AI company and someone shows up with you — I was just on a call with the CIO of one of the largest telcos the other day and we had a pod head, a pod leader come in, and they’re talking the language. They’re talking about the tech and that CIO is talking very deeply about what they want to do with this technology. It doesn’t work to have them bring in people and do another call and do — the people who are servicing should be engineers and technologists when it comes to AI, and that’s what an AI company would look like to a customer. So that’s a big change for us.
Chad Cooper: I have a question coming in actually by e-mail by Tom Blakey from KeyBanc. You mentioned 7% to 10% free cash flow margins and 16% to 19% adjusted EBITDA in the core by the end of ’23. What about the total business? When will non-core revenue go to zero?
John Collins: Broadly speaking, non-core revenue should be — will be worked on throughout the year, but the most — the largest components that still remain will exit the P&L in the second quarter.
Chad Cooper: Question from Ryan MacDonald at Needham. What incremental investments are needed to effectively sell to a new channel for LivePerson, physicians to start to license the WildHealth platform moving forward?
John Collins: the exact amounts and allocations of investments. I would note that we have set aside investment that is reflected in our guidance for both WildHealth and, of course, the generative AI integrations that we think will power our growth in the B2B core going forward.
Robert LoCascio: And the WildHealth business does burn a little bit of cash because of its growth rate. So we are funding for growth, not overfunding. Matt’s pretty prudent with the money, but we are — it’s a high-growth business and there’s an acquisition there that we’re doing. We do direct-to-consumer and then also they have a way to bring doctors in. They’re also working with other areas like hospitals. They’re starting to open that up. The other thing that’s exciting is we got Medicare and Medicaid, although Medicare is a tough group to work with sometimes, as we saw in Q4, but we’re also looking at private insurances and all that. So that will open up, cost of acquisition goes down. So there’s a lot of potential there right now. But there’s a lot of people in the world that want to pay out of pocket. There’s physicians who get — who want to be onboarded to the platform to change the game in how they’re providing health care to their patients.
Chad Cooper: I think that’s it for questions. Rob, do you want to wrap up?
Robert LoCascio: Sure. Just want to thank everyone for being here. I know this is a different type of quarterly call because we’re a different type of company. In 28 years of doing this, we’ve had 3 separate times in our history where an opportunity came, we were well positioned for it, but we had to make a lot of changes to free us to get there. And I want to bring also — obviously, Joe and Matt, thank you guys for being on a call. It’s like a high wire act on a quarterly call coming in because you mess up, something is going to happen to you, we’ll find you guys. But you did a great job, and I appreciate you showing the investments we’re making in the core, the investments we’re making in health care. And I think, once again, as shareholders, I think there’s very few AI companies that are public, purely AI.
